A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

This study will evaluate the pharmacokinetics and safety of Diluted and Undiluted Intravenous DA-5217 in healthy adult subjects.

Inclusion Criteria:

• Healthy adult male or female, 19 years to 45 years
• Weighing 50 kg or more, with a body mass index (BMI) of 18.5 kg/m2 to 29.9kg/m2
• The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate and complied with the precautions.

Exclusion Criteria:

• The subjects with existing or previous conditions that may influence the pharmacokinetics of drugs
• The subjects hypersensitive to any of the Investigational Product components or other drug components
• The subjects with clinically significant active chronic conditions
• The subjects with a positive urine drug test result or a history of drug abuse or dependence.
• The subjects who are pregnant or lactating